SI

EX-99.1

2 ex-991earningsreleaseq32026.htm

EX-99.1

Document

Exhibit 99.1

Shoulder Innovations Reports Third Quarter 2026 Financial Results and Raises Full Year Outlook

52% Year-to-Date 2026 Revenue Growth

Grand Rapids, MI – November 5, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter Financial Highlights

•Generated net revenue of $16.2 million in the third quarter, a 38% increase over the third quarter of 2025

•Achieved gross margin of 78.5% for the third quarter compared to 76.2% for the third quarter of 2025

•Increased average selling price of our implant systems to $7,616 in the third quarter, a 2% increase over the third quarter of 2025

•Increased full year 2026 net revenue guidance to $68 million to $70 million, representing growth of approximately 44% to 48% over full year 2025 net revenue

Recent Business Highlights

•Sold 2,126 total implant systems in the third quarter, an approximate 34% increase over the third quarter of 2025

•Completed the first surgical cases with InSet® Go, the company’s next-generation InSet® anatomic glenoid implant

•Received FDA 510(k) clearance for and initiated commercial launch of the N-22 humeral head, extending the company’s N-22 line for patients with metal hypersensitivity to anatomic procedures

•Announced exclusive partnership with ALM Ortho to develop additively manufactured solutions for severe deformity and complex revision cases

•Continued to expand the commercial leadership organization to support new territory expansion

•Promoted Jon Osborne to Chief Commercial Officer with responsibility for all elements of the company's commercial organization

•Announced a settlement agreement with Catalyst OrthoScience Inc. to resolve all outstanding patent litigation between the two companies

“Our third quarter results reflect the consistency of our commercial model, as we added new surgeons ahead of plan, grew volume within our existing customer base, and kept our product roadmap moving,” said Rob Ball, CEO of Shoulder Innovations. “This performance enabled us to again raise our outlook for the full year, and confirmed our conviction regarding our ability to grow market share through a differentiated approach to shoulder surgical care.”

Mr. Ball continued, “From a new product standpoint, we’re pleased to have recently completed the first successful cases with InSet Go, our next-generation glenoid implant. Beyond our own pipeline, our partners are extending what our platform can offer, with a new partnership bringing bespoke solutions for the most complex revision cases and our soft

tissue relationship positioning us to serve more of each shoulder specialist’s practice. As we head into the final quarter of 2026, the commercial organization we’ve built continues to perform, our pipeline has never been deeper, and we look forward to finishing the year strong and building on that momentum into 2027, including the planned FDA submission of InSet Neo, our shoulder-specific robotic platform.”

Third Quarter 2026 Financial Results

Net revenue in the third quarter of 2026 increased 38% to $16.2 million, compared to $11.8 million in the third quarter of 2025. The increase was primarily due to an increase in the number of implant systems sold, driven by new surgeon customers and higher utilization among existing customers, as well as an increase in the average selling price of implant systems.

Gross margin in the third quarter of 2026 was 78.5%, compared to 76.2% in the third quarter of 2025. The increase was due to increases in the average selling price of implant systems, as well as benefits from cost reduction programs.

Selling, general and administrative expenses in the third quarter of 2026 increased 14% to $17.1 million, compared to $15.1 million in the third quarter of 2025. The increase was primarily due to investments in the commercial organization and higher variable selling expenses, partially offset by lower legal expenses.

Research and development expenses in the third quarter of 2026 increased 107% to $3.2 million, compared to $1.5 million in the third quarter of 2025. The increase was due to investment in new product development efforts, including substantial work related to the InSet Neo robotic platform.

Operating loss in the third quarter of 2026 and 2025 was unchanged at $7.6 million, as higher gross profit was offset by increased operating expenses. Net loss in the third quarter of 2026 was $7.0 million, compared to a net loss of $8.7 million in the third quarter of 2025. The decrease in net loss was primarily due to changes in the fair value of the company's preferred stock warrant liability and convertible notes in the prior year.

Adjusted EBITDA in the third quarter of 2026 was a loss of $5.5

EX-99.1

2 ex-991earningsreleaseq22026.htm

EX-99.1

Document

Exhibit 99.1

Shoulder Innovations Reports Second Quarter 2026 Financial Results and Raises Full Year Outlook

Generates First Half 2026 Revenue Growth of 60%

Grand Rapids, MI – August 6, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the second quarter ended June 30, 2026.

Second Quarter Financial Highlights

•Generated net revenue of $17.2 million in the second quarter, a 56% increase over the second quarter of 2025

•Achieved gross margin of 78.3% for the second quarter compared to 76.2% for the second quarter of 2025

•Increased average selling price of our implant systems to $7,674 in the second quarter, a 5% increase over the second quarter of 2025

•Increased full year 2026 net revenue guidance to $67 million to $69 million, representing growth of approximately 42% to 46% over full year 2025 net revenue

Recent Business Highlights

•Sold 2,238 total implant systems in the second quarter, an approximate 50% increase over the second quarter of 2025

•Initiated full commercial launch of the N-22 glenosphere for patients with metal hypersensitivity

•Initiated full commercial launch of a new titanium plasma spray (TPS) baseplate line extension for reverse procedures

•Closed two new credit facilities for an aggregate amount of up to $50 million with Stifel Venture Banking, refinancing existing debt and adding undrawn working capital capacity

•Expanded commercial organization in the second quarter to support increased business scale

"Our second quarter results build on a strong start to the year and reflect remarkable momentum across every dimension of our business,” said Rob Ball, CEO of Shoulder Innovations. “We continued to rapidly onboard new surgeons against a large, underpenetrated market opportunity, deepened utilization within our existing surgeon base, and advanced a broad and increasingly differentiated product pipeline. This performance resulted in net revenue growth of 56% and implant volume growth of approximately 50%, enabling us to increase our outlook for the full year.”

Mr. Ball continued, “Our confidence in what lies ahead has never been stronger. The commercial organization we’ve built continues to perform, our innovation pipeline is growing, and our conviction in the team’s ability to execute is high. With a strengthened financial foundation following our recent debt refinancing, we believe Shoulder Innovations remains in the early stages of what we can accomplish in transforming shoulder surgical care, and we look forward to demonstrating that in the back half of 2026 and beyond.”

Second Quarter 2026 Financial Results

Net revenue in the second quarter of 2026 increased 56% to $17.2 million, compared to $11.0 million in the second quarter of 2025. The increase was due to an increase in the number of implant systems sold, as well as an increase in the number of customers.

Gross margin in the second quarter of 2026 was 78.3%, compared to 76.2% in the second quarter of 2025. The increase was was due to increases in the average selling price of implant systems, as well as benefits from negotiated cost reduction programs.

Selling, general and administrative expenses in the second quarter of 2026 increased 56% to $20.1 million, compared to $12.8 million in the second quarter of 2025. The increase was primarily due to investments in the commercial organization, higher variable selling expenses, and increased costs associated with becoming a public company.

Research and development expenses in the second quarter of 2026 increased 141% to $3.4 million, compared to $1.4 million in the second quarter of 2025. The increase was due to investment in new product development efforts, including development related to the robotic platform strategic partnership.

Operating loss in the second quarter of 2026 was $10.0 million, compared to a loss of $5.9 million in the second quarter of 2025. Net loss in the second quarter of 2026 was $10.2 million, compared to a net loss of $19.2 million in the second quarter of 2025. The increase in operating loss was primarily related to increased operating expenses, while the decrease in net loss was primarily due to a significant prior year charge related to changes in the fair value of the company's preferred stock warrant liability and Series E purchase option.

Adjusted EBITDA in the second quarter of 2026 was a loss of $8.0 million, compared to a loss of $18.1 million in the second quarter of 2025. The decrease in loss was primarily due to a significant prior year charge related to changes in the fair value of the company's preferred stock warrant liability and Series E purchase option.

As of June 30, 2026, cash and cash equivalents, and marketable securities totaled $99.0 million.

2026 Financial Outlook

EX-99.1

2 ex-991earningsreleaseq12026.htm

EX-99.1

Document

Exhibit 99.1

Shoulder Innovations Reports First Quarter 2026 Financial Results and Raises Full Year Outlook

Generates First Quarter Net Revenue Growth of 65% Year-Over-Year

Grand Rapids, MI – May 13, 2026 – Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the first quarter ended March 31, 2026.

First Quarter Financial Highlights

•Generated net revenue of $16.7 million in the first quarter, a 65% increase over the first quarter of 2025

•Achieved gross margin of 77.7% for the first quarter compared to 76.9% for the first quarter of 2025

•Increased average selling price of our implant systems to $7,650 in the first quarter, a 9% increase over the first quarter of 2025

•Increased full year 2026 net revenue guidance to $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue

Recent Business Highlights

•Sold 2,184 total implant systems in the first quarter, a 51% increase over the first quarter of 2025

•Initiated full commercial launch of the InSet™ I-135RFX Humeral Stem following a successful limited user release and FDA clearance of additional fracture indications

•Expanded commercial organization in the first quarter to support increased business scale

"We are very pleased with our first quarter performance, which reflects accelerating revenue growth and intensifying commercial momentum across our entire organization,” said Rob Ball, CEO of Shoulder Innovations. “Net revenue growth of 65%, implant volume growth of 51%, and continued improvement in gross margin demonstrate the strength and efficiency of our rapidly expanding ecosystem.”

Mr. Ball continued, “Building on this traction, recent product portfolio milestones, including the full commercial launch of our InSet™ I-135RFX Humeral Stem, meaningfully extend the comprehensive suite of solutions we offer surgeons and their patients. This disciplined financial and operational execution to start the year provides us with increased confidence in the trajectory of the business and enables us to increase our full year 2026 revenue guidance.”

First Quarter 2026 Financial Results

Net revenue in the first quarter of 2026 increased 65% to $16.7 million, compared to $10.1 million in the first quarter of 2025. The increase was due to an increase in the number of implant systems sold, as well as an increase in the number of customers.

Gross margin in the first quarter of 2026 was 77.7%, compared to 76.9% in the first quarter of 2025.

Selling, general and administrative expenses in the first quarter of 2026 increased 73% to $18.2 million, compared to $10.5 million in the first quarter of 2025. The increase was primarily due to investments in the commercial organization, higher variable selling expenses, and increased costs associated with becoming a public company.

Research and development expenses in the first quarter of 2026 increased 137% to $3.8 million, compared to $1.6 million in the first quarter of 2025. The increase was due to investment in new product development efforts, including a milestone payment and development related to the robotic platform strategic partnership.

Operating loss in the first quarter of 2026 was $9.0 million, compared to a loss of $4.3 million in the first quarter of 2025. Net loss in the first quarter of 2026 was $8.4 million, compared to a net loss of $4.7 million in the first quarter of 2025. The increase in operating loss and net loss was primarily related to increased operating expenses.

Adjusted EBITDA in the first quarter of 2026 was a loss of $7.0 million, compared to a loss of $3.5 million in the first quarter of 2025. The increase in loss was primarily due to the aforementioned increased operating expenses.

As of March 31, 2026, cash and cash equivalents, and marketable securities totaled $108.5 million.

2026 Financial Outlook

Shoulder Innovations expects net revenue for the full year 2026 to be in the range of $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue. This compares to prior guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.

Conference Call

Management will host a conference call today, May 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the company’s first quarter 2026 financial results. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the "Investor Relations" section of the Shoulder Innovations website at https://ir.shoulderinnovations.com.

Use of Non-GAAP Financial Measures